Citadel Advisors LLC Purchases New Position in Adamas Pharmaceuticals, Inc. (ADMS)

Citadel Advisors LLC purchased a new stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 34,628 shares of the specialty pharmaceutical company’s stock, valued at approximately $606,000. Citadel Advisors LLC owned approximately 0.15% of Adamas Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. American International Group Inc. grew its stake in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 682 shares in the last quarter. Wells Fargo & Company MN grew its stake in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 3,358 shares in the last quarter. Alps Advisors Inc. grew its stake in Adamas Pharmaceuticals by 6.7% in the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after purchasing an additional 1,272 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after purchasing an additional 41,436 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 1,563 shares in the last quarter. Hedge funds and other institutional investors own 69.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://transcriptdaily.com/2017/10/08/citadel-advisors-llc-purchases-new-position-in-adamas-pharmaceuticals-inc-adms.html.

Adamas Pharmaceuticals, Inc. (ADMS) opened at 23.11 on Friday. The stock’s 50 day moving average price is $20.28 and its 200 day moving average price is $17.61. Adamas Pharmaceuticals, Inc. has a 52 week low of $12.10 and a 52 week high of $24.18. The company’s market capitalization is $520.30 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. The firm’s quarterly revenue was down 90.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.78) earnings per share. Analysts anticipate that Adamas Pharmaceuticals, Inc. will post ($3.77) earnings per share for the current year.

A number of research firms have weighed in on ADMS. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, William Blair restated an “ourperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and an average price target of $39.50.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply